Bolt Biotherapeutics to Participate in September Investor Conferences
06 9월 2023 - 5:15AM
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage
biopharmaceutical company developing novel immunotherapies for the
treatment of cancer, today announced that management will
participate in two upcoming conferences in September:
- Morgan Stanley 21st
Annual Global Healthcare Conference Fireside chat
on Tuesday, Sept. 12, at 3:35 p.m. EDT (12:35 p.m. PDT)
- H.C. Wainwright 25th
Annual Global Investment Conference Management
will be available for one-on-one meetings with investors on
Wednesday, Sept. 13
A live webcast of the Morgan Stanley fireside chat will be
available on the Events and Presentations page of Bolt’s website
at www.boltbio.com. Archived replays will be available for 30
days following the event.
About Bolt Biotherapeutics, Inc. Bolt
Biotherapeutics is a clinical-stage biopharmaceutical company
developing novel immunotherapies for the treatment of cancer. Bolt
Biotherapeutics’ pipeline candidates are built on the Company’s
deep expertise in myeloid biology and cancer drug development. The
Company’s pipeline includes BDC-1001, a HER2-targeting Boltbody™
Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a
myeloid-modulating antibody, and multiple Boltbody ISAC
collaboration programs. BDC-1001 is currently in Phase 2 clinical
development following the successful completion of a Phase 1
dose-escalation trial that demonstrated tolerability and early
clinical efficacy. BDC-3042, an agonist antibody targeting
Dectin-2, is expected to initiate a Phase 1 trial in the second
half of 2023. In preclinical development, BDC-3042 demonstrated the
ability to convert tumor-supportive macrophages to
tumor-destructive macrophages. Bolt Biotherapeutics is also
developing multiple Boltbody™ ISACs in strategic collaborations
with leading biopharmaceutical companies. For more information,
please visit https://www.boltbio.com/For more information, please
visit https://www.boltbio.com/
Investor Relations and Media Contacts:
Paige KellyStern Investor Relations,
Inc.212-698-8699paige.kelly@sternir.com
David SchullRusso Partners,
LLC646-942-5631david.schull@russopartnersllc.com
Bolt Biotherapeutics (NASDAQ:BOLT)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Bolt Biotherapeutics (NASDAQ:BOLT)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024